Patents by Inventor Kazimierz A. Wisniewski

Kazimierz A. Wisniewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION
    Publication number: 20230124105
    Abstract: The present invention relates to pharmaceutical compositions having improved stability.
    Type: Application
    Filed: July 12, 2022
    Publication date: April 20, 2023
    Applicant: Ferring B.V.
    Inventors: Anders Nilsson, Mattias Malm, Kazimierz Wisniewski, Britta Siekmann
  • Vasopressin-2 receptor agonists
    Patent number: 10745443
    Abstract: Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 18, 2020
    Assignee: FERRING B.V.
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Pierre Riviere
  • VASOPRESSIN-2 RECEPTOR AGONISTS
    Publication number: 20190194257
    Abstract: Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.
    Type: Application
    Filed: September 27, 2018
    Publication date: June 27, 2019
    Applicant: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Pierre Riviere
  • Vasopressin-2 receptor agonists
    Patent number: 10131692
    Abstract: Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 20, 2018
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Pierre Riviere
  • NEW METHODS FOR MAKING BARUSIBAN AND ITS INTERMEDIATES
    Publication number: 20180282367
    Abstract: The present invention relates to new solid phase peptide methods for synthesizing analogues that exhibit oxytocin antagonist activity, specifically Barusiban and its intermediates. Specifically, the present invention relates to a solid phase process for preparing a compound having the formula c[AA1-AA6]-AA7-ol, wherein AA1 is propionic acid, AA2 is preferably D-Trp, AA3 is Ile, AA4 is preferably AlloIle, AA5 is Asn, AA6 is hCy, and AA7 is preferably N-Me-Orn-ol, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 4, 2018
    Inventors: Leila Malik, Kazimierz Wisniewski, Chantal Devin
  • CGRP antagonist peptides
    Patent number: 9969775
    Abstract: This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar1, Ar2, Ar3, R1, R2, and R3 are defined in the specification. The compounds of formula (I) can be used as CGRP antagonists and can be used to treat migraine.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: May 15, 2018
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Guangcheng Jiang, Aleksandr K. Rabinovich, Javier J. Sueiras-Diaz
  • CGRP Antagonist Peptides
    Publication number: 20180002378
    Abstract: This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar1, Ar2, Ar3, R1, R2, and R3 are defined in the specification.
    Type: Application
    Filed: January 6, 2016
    Publication date: January 4, 2018
    Inventors: Kazimierz WISNIEWSKI, Guangcheng JIANG, Aleksandr K. RABINOVICH, Javier J. SUEIRAS-DIAZ
  • V1a receptor agonists
    Patent number: 9644000
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: May 9, 2017
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20170106043
    Abstract: The present invention relates to pharmaceutical compositions having improved stability.
    Type: Application
    Filed: December 28, 2016
    Publication date: April 20, 2017
    Inventors: Anders Nilsson, Mattias Malm, Kazimierz Wisniewski, Britta Siekmann
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20170106044
    Abstract: The present invention relates to pharmaceutical compositions having improved stability.
    Type: Application
    Filed: December 28, 2016
    Publication date: April 20, 2017
    Inventors: Anders Nilsson, Mattias Malm, Kazimierz Wisniewski, Britta Siekmann
  • Pharmaceutical composition
    Patent number: 9566311
    Abstract: The present invention relates to pharmaceutical compositions having improved stability.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: February 14, 2017
    Assignee: Ferring B.V.
    Inventors: Britta Siekmann, Mattias Malm, Anders Nilsson, Kazimierz Wisniewski
  • V1A receptor agonists
    Patent number: 9388214
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: July 12, 2016
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Galyean
  • V1A RECEPTOR AGONISTS
    Publication number: 20160122386
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 5, 2016
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Galyean
  • VASOPRESSIN-2 RECEPTOR AGONISTS
    Publication number: 20150307555
    Abstract: Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.
    Type: Application
    Filed: July 25, 2014
    Publication date: October 29, 2015
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Pierre Riviere
  • V1a Receptor Agonists
    Publication number: 20150126432
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • Compounds
    Patent number: 8883965
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: November 11, 2014
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Robert Felix Galyean
  • Peptidic vasopressin receptor agonists
    Patent number: 8778881
    Abstract: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: July 15, 2014
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Regent LaPorte, Robert Felix Galyean, Pierre J.M. Riviere
  • Oxytocin receptor agonists
    Patent number: 8748564
    Abstract: The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: June 10, 2014
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Claudio Daniel Schteingart, Sudarkodi Alagarsamy, Robert Galyean
  • Peptidic GLP-2 agonists
    Patent number: 8580918
    Abstract: Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: November 12, 2013
    Assignee: Ferring B.V.
    Inventors: Sudarkodi Alagarsamy, Guangcheng Jiang, Pierre Riviere, Claudio Daniel Schteingart, Javier Sueiras-Diaz, Kazimierz Wisniewski
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20130210746
    Abstract: The present invention relates to pharmaceutical compositions having improved stability.
    Type: Application
    Filed: September 29, 2011
    Publication date: August 15, 2013
    Applicant: FERRING B.V.
    Inventors: Britta Siekmann, Mattias Malm, Anders Nilsson, Kazimierz Wisniewski